Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MiNK Therapeutics, Inc. (INKT : NSDQ)
 
 • Company Description   
MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York.

Number of Employees: 23

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.23 Daily Weekly Monthly
20 Day Moving Average: 14,649 shares
Shares Outstanding: 3.99 (millions)
Market Capitalization: $28.82 (millions)
Beta: 0.19
52 Week High: $13.79
52 Week Low: $4.56
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.80% -6.18%
12 Week -4.60% -19.96%
Year To Date 3.77% -2.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
149 Fifth Avenue
-
New York,NY 10010
USA
ph: 212-994-8250
fax: -
investor@minktherapeutics.com http://www.minktherapeutics.com
 
 • General Corporate Information   
Officers
Jennifer S. Buell - President; Chief Executive Officer and Director
Garo H. Armen - Chairman
Christine M. Klaskin - Treasurer
Peter Behner - Director
Brian Corvese - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 603693201
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 3.99
Most Recent Split Date: 1.00 (0.10:1)
Beta: 0.19
Market Capitalization: $28.82 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.45 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.98 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 36.36%
vs. Previous Quarter: -12.90%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -140.72
12/31/24 - -142.32
Current Ratio
06/30/25 - -
03/31/25 - 0.30
12/31/24 - 0.72
Quick Ratio
06/30/25 - -
03/31/25 - 0.30
12/31/24 - 0.72
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -5.49
12/31/24 - -4.94
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©